Search Results
Your search for ASCO matches 21353 pages
Showing 19251 - 19300‘Frozen Sleep’ as Cancer Treatment, Springfield, Illinois, 1939
Through the Lens of Oncology History: A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photo below is from the volume titled “The Radium...
Hormonal Therapy and Risk of Ovarian Cancer
Ovarian cancer is the second most common gynecologic malignancy in the United States, with an estimated 21,290 new cases expected this year. Ovarian cancer causes 5% of all cancer deaths in women, making it responsible for the highest number of gynecologic cancer deaths.1 Age, family history, and...
Deciphering the Genetic Variability of Cancer to Advance Precision Oncology Care
In 2014, Memorial Sloan Kettering Cancer Center (MSKCC) in New York opened the Marie-Josée and Henry R. Kravis Center for Molecular Oncology with the sole purpose of expediting the translation of novel molecular discoveries into clinical innovations to turn the goal of precision oncology care into...
National Cancer Institute Pulls PSA Data From SEER
In a move that reverberated through much of the cancer research community, the National Cancer Institute (NCI) recently announced that it had removed all prostate-specific antigen (PSA) data from its current Surveillance, Epidemiology, and End Results (SEER) data submission and associated...
Help Your Patients Catch Up on the Latest Research From the 2015 ASCO Annual Meeting
Direct your patients to www.cancer.net/blog for podcasts with ASCO experts discussing the research that was presented at the 2015 ASCO Annual Meeting. This series of “Research Round Up” podcasts provides the latest information on treatment and care for people with cancer and will help your patients ...
2015 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...
New Resources Developed by ASCO’s Community Research Forum
The ASCO Community Research Forum (CRF) is a solution-oriented venue for community research sites to overcome barriers to conducting clinical trials. Each year, the CRF council, comprising ASCO member volunteers, selects topic areas and specific solution-oriented projects for working groups to make ...
Registration Open for 2015 Community Research Forum Annual Meeting
Registration is now open for the Community Research Forum (CRF) Annual Meeting, which will take place on September 20 to 21, at ASCO Headquarters in Alexandria, Virginia. Join fellow physician investigators and research staff from all types of community-based research sites and programs to discuss...
ASCO Releases Updated, Expanded Set of Survivorship Care Planning Templates
ASCO has issued an updated and expanded set of treatment and survivorship care plan templates for oncology care professionals and patients with cancer. The templates serve to enhance ASCO’s existing suite of tools to help providers and patients fully plan a course of cancer treatment, from...
ASCO Releases Payment Reform Proposal to Support Higher Quality, More Affordable Cancer Care
ASCO released a proposal to significantly improve the quality and affordability of care for cancer patients. ASCO’s Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP) proposal is designed to simultaneously improve services to patients and ...
Adjuvant Chemotherapy Proves Effective in Localized, High-Risk Prostate Cancer
For the first time, a large randomized trial has suggested that overall survival is improved by the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in men with localized, high-risk, hormone-sensitive prostate cancer. Docetaxel has been used to treat metastatic...
Ibrutinib Plus Bendamustine/Rituximab Called a New Standard in Patients With Previously Treated CLL
The addition of ibrutinib (Imbruvica) to standard therapy with bendamustine (Treanda)/rituximab (Rituxan) significantly reduced the risk of disease progression or death and overall response rates compared with bendamustine/rituximab alone in previously treated chronic lymphocytic leukemia...
Two Factors Predict for Recurrent Venous Thromboembolism in Patients With Cancer
Patients with cancer who develop venous thromboembolism are at high risk of such obstructive disease recurring despite adequate anticoagulation. A prespecified analysis of the CATCH trial identified two major predictors of recurrence: venous compression by the tumor and a diagnosis of hepatobiliary ...
Eribulin Improves Overall Survival in Difficult-to-Treat Sarcoma Types
Eribulin (Halaven), a cytotoxic agent approved for advanced/metastatic breast cancer, may improve overall survival for patients with two common and difficult-to-treat forms of advanced/metastatic sarcoma, investigators reported at the 2015 ASCO Annual Meeting.1 Eribulin is a microtubule inhibitor...
Expert Point of View: Lynn Schuchter, MD, and Vernon Sondak, MD
Lynn Schuchter, MD, of the University of Pennsylvania, Philadelphia, a designated ASCO expert, commented at the press briefing that the results might apply to a select group of patients concerned about lymphedema but not yet to the broader population. “I would say that this is a really important...
Not All Stage III Melanoma Patients Need Complete Nodal Dissection
Complete lymph node dissection did not improve survival in melanoma patients randomized to this practice, vs sentinel lymph node biopsy alone, German investigators reported at the 2015 ASCO Annual Meeting.1 “This is the first study that tested the typical recommendation of complete lymph node...
Routine Resection of Cavity Shave Margins Halved Reexcision Rates in Breast Cancer
Taking additional tissue circumferentially around the cavity left by partial mastectomy (“cavity shave margins”) cut the rate of positive margins by nearly 50% and the rate of reexcision for margin clearance by more than 50% compared with standard partial mastectomy with or without the surgeon...
Expert Point of View: Joseph A. Sparano, MD, and Don Dizon, MD
Joseph A. Sparano, MD, Professor of Medicine and Women’s Health at the Albert Einstein College of Medicine, New York, was the formal discussant of the study and commented, “These findings confirm the strong signal observed in the phase II PALOMA1 trial, and there were no subgroups that did not...
Expert Point of View: Suzanne Lentzsch, MD, PhD
Suzanne Lentzsch, MD, PhD, Director of the Multiple Myeloma and Amyloidosis Program, Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, served as the study’s discussant. She called the 29% response rate in this heavily pretreated or refractory population...
Single-Agent Daratumumab Activity Deemed ‘Remarkable’ in Refractory Multiple Myeloma
Heavily pretreated patients with multiple myeloma achieved rapid, durable, and deepening responses to the anti-CD38 monoclonal antibody daratumumab, in a phase II study presented at the 2015 ASCO Annual Meeting.1 “Daratumumab showed remarkable single-agent activity in heavily pretreated and...
ASCO Releases Details of Its Conceptual Framework for Assessing Value in Cancer Care
Defining and ensuring the delivery of high-value oncology care has been one of ASCO’s major goals for more than a decade. In 2007, ASCO formed the Task Force on the Cost of Cancer Care, now called the Value in Cancer Care Task Force, to identify the drivers of the increasing costs of oncology care...
Considering Clonality in Precision Medicine
Precision cancer medicine entails treating patients based upon the molecular characteristics of their tumor. One could argue that we have been tailoring therapeutic regimens based upon tumor characteristics for years, whether it be treating patients based upon disease subtypes determined by...
Elective Neck Dissection Beats Watch and Wait Approach in Early Oral Cancer
Elective neck dissection of node-negative early-stage oral cancer at the time of primary surgery improves overall survival and disease-free survival compared with therapeutic neck dissection (ie, therapeutic neck dissection at the time of nodal relapse, or “watch and wait” approach), according to a ...
Frederick Pei Li, MD, Pioneer of Cancer Genetics, Dies at 75
Frederick Pei Li, MD, who helped inaugurate the era of cancer genetics by demonstrating that people can inherit a genetic susceptibility to develop certain malignancies, died on June 12 at the age of 75. A Professor at Dana-Farber Cancer Institute, Harvard Medical School, and Harvard T.H. Chan...
Date of Last Chemotherapy Is Not a Proxy for Deciding When to Stop Treating Metastatic NSCLC
“Patients, their families, and oncologists recognize the administration of chemotherapy near death as aggressive and poor-quality care,” William F. Pirl, MD, MPH, and colleagues from Massachusetts General Hospital, Boston, wrote in the Journal of Oncology Practice. “However, rates have been slowly...
Expect and Encourage Questions About the Benefits and Harms of Cancer Screening
Issuing advice for high-value care in screening for five common cancers, the High Value Care Task Force of the American College of Physicians (ACP) stated: “The target audience for this paper is all clinicians. The target patient population is average-risk, asymptomatic patients.” “What we tried...
Agreement on High-Value Screening for Five Common Cancers
Finding agreement on high-value cancer screening among organizations publishing screening guidelines, the American College of Physicians (ACP) issued advice listing the least-intensive screening strategies that all the organizations recommend—as well as strategies not recommended—for five common...
2015 Oncology Meetings
JULY Gynecologic Oncology GroupJuly 15-19 • Denver, Colorado For more information: www.gog.org/meetinginformation.html 14th Annual International Congress on the Future of Breast Cancer®July 16-18 • Huntington Beach, California For more information:...
Clara D. Bloomfield, MD, FASCO: Never One to Back Down From a Challenge
Clara D. Bloomfield, MD, FASCO, always sat in the front row at school. She grew up during a rigidly paternalist period in American society, and her early feminist leanings were brushed aside as grade-school adventures. The medical school lecture room of the 1960s was a male-dominated culture, and...
First Winners of Tri-Institutional Breakout Awards Announced
Six young scientists at Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medical College have been named the inaugural winners of a new prize established to recognize postdoctoral investigators in the life sciences. The Tri-Institutional Breakout Awards for Junior...
Translating Study Recommendations Into Medicare Coverage
Lung cancer doggedly remains the leading cause of cancer-related death in the United States. This grim mortality figure is due, in part, to a lack of early detection methods; more than half of all lung cancers have metastasized at the time of diagnosis. For decades, lung cancer advocates lobbied...
Roberto Pili, MD, Expert in Prostate, Renal, and Bladder Cancers, Joins Indiana University Simon Cancer Center
Roberto Pili, MD, a nationally recognized expert in prostate, renal, and bladder cancers, has joined the Indiana University (IU) Melvin and Bren Simon Cancer Center. Dr. Pili is the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine and Researcher at the IU...
ASCO Members, Public Working Together to ‘Take Down’ Cancer
From Wrigley Field to McCormick Place, Chicago residents and visitors felt the energy surrounding the launch of The Campaign to Conquer Cancer during the ASCO 2015 Annual Meeting. The Conquer Cancer Foundation of the American Society of Clinical Oncology (CCF) threw out the ceremonial first pitch...
ASCO Releases Payment Reform Proposal to Support Higher Quality, More Affordable Cancer Care
ASCO has released a proposal to significantly improve the quality and affordability of care for cancer patients. Expanding on a payment model circulated last year, the ASCO proposal would fundamentally restructure the way oncologists are paid for cancer care in the United States, by providing...
ASCO Recommends Palliative Care as Part of Cancer Treatment
ASCO recommends that doctors, patients, and caregivers talk about palliative care soon after diagnosis for any patient with metastatic cancer and for patients with many and/or severe symptoms. ASCO has developed a resource to help patients understand the importance of palliative care from diagnosis ...
ASCO QOPI® Certification Program Benefits Oncology Practices and Patients
Christa Braun-Inglis, MS, NP, has seen her last three practices certified through ASCO’s Quality Oncology Practice Initiative (QOPI®). Ms. Braun-Inglis, a nurse practitioner with Kaiser Hawaii Region, was not solely responsible for the designations, although she helped some of the practices become...
2015 Breast Cancer Symposium to Encourage Collaboration in Patient Care, Education, and Research
ASCO’s educational symposia have historically provided attendees with a forum for learning and discussion, demonstrating ASCO’s commitment to promoting a network of global oncology expertise. The 2015 Breast Cancer Symposium, to be held in San Francisco, California, from Friday, September 25, to...
Bert Vogelstein, MD, Receives 2015 Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson named Bert Vogelstein, MD, of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center, and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than 2 ...
Pembrolizumab in Advanced NSCLC: The Promise of Immune Checkpoint Inhibitors
Drugs targeting the immune-checkpoint pathways have shown promising activity in non–small cell lung cancer (NSCLC). In a recent article in The New England Journal of Medicine, Garon and colleagues reported the results of the KEYNOTE-001 clinical trial evaluating single-agent pembrolizumab...
Predicting Recurrence After Surgery in Renal Cell Carcinoma: 16-Gene Assay Recurrence Score Ushers in New Era
In a study reported in The Lancet Oncology and reviewed in this issue of The ASCO Post, Brian Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues showed that a 16-gene assay recurrence score could predict postoperative outcome in patients with stage I to III clear cell renal...
Five Presidential Appointees Named to National Cancer Advisory Board
President Barack Obama recently announced his intent to nominate the following individuals to the National Cancer Advisory Board: Peter C. Adamson, MD; Yuan Chang, MD; Timothy J. Ley, MD; Deborah Watkins Bruner, RN, PhD, FAAN; and Max S. Wicha, MD. Peter C. Adamson, MD Dr. Adamson is Attending...
Oncolytic Immunotherapy in Melanoma: It’s Not All About PD-1
The benefit from immune-directed therapies in patients with advanced melanoma is not limited to the exploding field of checkpoint inhibitors. According to Robert Andtbacka, MD, Associate Professor of Surgical Oncology, at the Huntsman Cancer Institute at the University of Utah, Salt Lake City,...
Poliovirus for Glioblastoma Grabs National Attention
Researchers at The Preston Robert Tisch Brain Tumor Center at Duke University are being barraged by patients wishing to enroll in their clinical trial of an engineered poliovirus for recurrent glioblastoma. This comes as a result of a CBS 60 Minutes interview with lead researcher Matthias...
Cost of Immunotherapy Projected to Top $1 Million per Patient per Year
If new immunotherapy combinations were administered to the half a million Americans dying of cancer each year, the nation’s price tag for treating them—for just 1 year—could top $174 billion, according to projections by Leonard Saltz, MD, Chief of Gastrointestinal Oncology and Chair of the Pharmacy ...
Investigators Update PVS-RIPO Data in Glioblastoma
At the 2015 ASCO Annual Meeting, Annick Desjardins, MD, Associate Professor of Neurology at Duke University Medical Center, presented a brief update on the ongoing study of oncolytic PVS-RIPO in glioblastoma, which now includes 24 patients.1 The median age of enrolled patients is 57, most have a...
Pacritinib for Myelofibrosis: Effective in Patients With Thrombocytopenia
An emerging JAK inhibitor, pacritinib, appears not only effective in a broad population of patients with myelofibrosis but also among a subset with very low platelet counts, investigators from the global phase III PERSIST-1 trial reported at the 2015 ASCO Annual Meeting.1 “There is a huge unmet...
UAB Study on Lay Navigation Program Shows Trend Toward Cost Savings
Researchers from the University of Alabama at Birmingham (UAB) presented preliminary findings of an observational study indicating a rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program. The study was presented at this year’s ASCO Annual ...
Lenvatinib/Everolimus: Robust Combination in Metastatic Renal Cell Carcinoma
The combination of lenvatinib (Lenvima) plus everolimus (Afinitor) significantly extended progression-free survival compared with everolimus alone in metastatic renal cell carcinoma, according to a randomized phase II trial.1 Median progression-free survival for patients who received the...
Anastrozole and Tamoxifen: Both Options for Ductal Carcinoma in Situ
Anastrozole was found to be at least as safe and effective as tamoxifen in preventing breast cancer recurrence in women with ductal carcinoma in situ, in the large NSABP B-35/SWOG-35 study.1 Among all women in the trial, however, the 10-year breast cancer–free interval rates were higher in women...
Ado-Trastuzumab Emtansine Fails to Replace Standard of Care in First-Line Metastatic Breast Cancer
Results are now in for the phase III MARIANNE trial. Although ado-trastuzumab emtansine (formerly known as T-DM1, Kadcyla) proved noninferior to trastuzumab (Herceptin) plus a taxane in the first-line metastatic breast cancer setting, it performed no better than the standard of care.1 “T-DM1 and...
